Polyamines detection with MR spectroscopy to increase diagnostic specifity in prostate cancer
- Conditions
- 10038597Prostate cancer.
- Registration Number
- NL-OMON40868
- Lead Sponsor
- Antoni van Leeuwenhoek Ziekenhuis
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 10
Inclusion Criteria
Patients with biopsy*proven prostate cancer who are eligible for a brachytherapy screening MRI exam of the prostate with an endorectal coil.
Exclusion Criteria
• Contra-indications for a MRI exam according to the standard protocol for the screening of patients with prostate cancer
• Treatment of prostate cancer prior to the MRI exams, including hormonal therapy and trans-urethral resection (TURP)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>To show the feasibility of acquiring 1H MRSI in prostate with reduced chemical<br /><br>shift artifacts at 3T using the FOCI RF pulses in a editing semi-LASER<br /><br>sequence. Quantification for comparison of the metabolite concentrations will<br /><br>be obtained with the LC model.<br /><br></p><br>
- Secondary Outcome Measures
Name Time Method <p>N.A</p><br>
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does MR spectroscopy detection of polyamines (e.g., ODC1 activity) improve diagnostic specificity in prostate cancer (NL-OMON40868)?
What is the comparative effectiveness of polyamine MR spectroscopy versus standard-of-care diagnostics like PSA testing in prostate cancer?
Which biomarkers correlate with polyamine levels detected via MR spectroscopy in prostate cancer subtypes (e.g., Gleason score 7+)?
What are the safety profiles of MR spectroscopy-based polyamine detection in prostate cancer patients (NL-OMON40868)?
Are there other compounds or imaging methods targeting polyamine pathways (e.g., DFMO, AMD1 inhibitors) in prostate cancer treatment?